上世纪蜱传脑炎 (TBE)是欧洲常见的病毒性中枢神经系统 (CNS)疾病 ,每年有数百例住院病例 ,致病因子是蜱传脑炎病毒 (TBEV) ,一种由蜱传播的黄病毒。2 0世纪 70年代早期开发了第一种组织培养疫苗 ,该疫苗上市使用 30年以来取得了良好的效果 ,显著降低了中欧 TBE的发病率 ,尤其是奥地利。本文论述了 TBE疫苗近年来在生产用毒种和生产工艺上的改进和临床效力评价 Tick ​​borne encephalitis (TBE), a common viral central nervous system (CNS) disease in Europe, has hundreds of hospitalized cases each year. The causative agents are tick-borne encephalitis virus (TBEV), a tick-borne Flavivirus. The first tissue culture vaccine was developed in the early 1970s and has achieved good results since it was available for 30 years, significantly reducing the incidence of TBE in Central Europe, especially in Austria. This article discusses the TBE vaccine in recent years in the production of toxic species and production processes to improve and evaluate the clinical efficacy